124 related articles for article (PubMed ID: 3750371)
21. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
[TBL] [Abstract][Full Text] [Related]
22. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
Chest; 1999 Oct; 116(4):984-90. PubMed ID: 10531163
[TBL] [Abstract][Full Text] [Related]
23. High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients.
Huang WH; Hung CC; Yang CW; Huang JY
Ther Apher Dial; 2012 Aug; 16(4):361-7. PubMed ID: 22817125
[TBL] [Abstract][Full Text] [Related]
24. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
[TBL] [Abstract][Full Text] [Related]
25. Studies of the elevated extracellular concentration of cyclic AMP in uremic man.
Hamet P; Stouder DA; Ginn HE; Hardman JG; Liddle GW
J Clin Invest; 1975 Aug; 56(2):339-45. PubMed ID: 168232
[TBL] [Abstract][Full Text] [Related]
26. Hemodialysis of doxepin and desmethyldoxepin in uremic patients.
Faulkner RD; Senekjian HO; Lee CS
Artif Organs; 1984 May; 8(2):151-5. PubMed ID: 6732542
[TBL] [Abstract][Full Text] [Related]
27. Effects of reduced dialysis fluid flow in hemodialysis.
Kashiwagi T; Sato K; Kawakami S; Kiyomoto M; Enomoto M; Suzuki T; Genei H; Nakada H; Iino Y; Katayama Y
J Nippon Med Sch; 2013; 80(2):119-30. PubMed ID: 23657065
[TBL] [Abstract][Full Text] [Related]
28. Effect of hemodialysis on serum concentrations of HPLC-analyzed accumulating solutes in uremia.
Schoots AC; Peeters JA; Gerlag PG
Nephron; 1989; 53(3):208-17. PubMed ID: 2507950
[TBL] [Abstract][Full Text] [Related]
29. pO2 and pCO2 increment in post-dialyzer blood: the role of dialysate.
Sombolos KI; Bamichas GI; Christidou FN; Gionanlis LD; Karagianni AC; Anagnostopoulos TC; Natse TA
Artif Organs; 2005 Nov; 29(11):892-8. PubMed ID: 16266303
[TBL] [Abstract][Full Text] [Related]
30. Effect of hemodialysis on total body clearance of chloramphenicol.
Slaughter RL; Cerra FB; Koup JR
Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
[TBL] [Abstract][Full Text] [Related]
31. Netilmicin pharmacokinetics in uremic patients undergoing hemodialysis.
Scatizzi A; Basile C; Strippoli P; Di Maggio A; Orbello G; Lodeserto C; Triarico A; Mingrone G; Longo S; Curino E
Chemioterapia; 1986 Oct; 5(5):327-9. PubMed ID: 3791480
[TBL] [Abstract][Full Text] [Related]
32. HPLC study of uremic fluids related to optical dialysis adequacy monitoring.
Lauri K; Tanner R; Jerotskaja J; Luman M; Fridolin I
Int J Artif Organs; 2010 Feb; 33(2):96-104. PubMed ID: 20306436
[TBL] [Abstract][Full Text] [Related]
33. Liquid-chromatographic determination of inosine, xanthine, and hypoxanthine in uremic patients receiving hemodialysis treatment.
Severini G; Aliberti LM
Clin Chem; 1987 Dec; 33(12):2278-80. PubMed ID: 3690845
[TBL] [Abstract][Full Text] [Related]
34. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis.
Fontán MP; Rodríguez-Carmona A; Cordido F; García-Buela J
Am J Kidney Dis; 1999 Nov; 34(5):824-31. PubMed ID: 10561137
[TBL] [Abstract][Full Text] [Related]
35. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis.
Kario K; Matsuo T; Yamada T; Matsuo M
Thromb Haemost; 1994 Mar; 71(3):275-9. PubMed ID: 8029788
[TBL] [Abstract][Full Text] [Related]
36. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
[TBL] [Abstract][Full Text] [Related]
37. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
[TBL] [Abstract][Full Text] [Related]
38. Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.
Jang SM; Cardone KE; Nolin TD; Mason DL; Grabe DW
BMC Nephrol; 2014 Dec; 15():204. PubMed ID: 25526750
[TBL] [Abstract][Full Text] [Related]
39. Removal of phenytoin by hemodialysis in uremic patients.
Martin E; Gambertoglio JG; Adler DS; Tozer TN; Roman LA; Grausz H
JAMA; 1977 Oct; 238(16):1750-3. PubMed ID: 578272
[TBL] [Abstract][Full Text] [Related]
40. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
Asad SN; Olmer AJ; Letteri JM
Miner Electrolyte Metab; 1984; 10(5):333-6. PubMed ID: 6493162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
